Regional differences between Japan and the Netherlands in atopic dermatitis patient-reported outcome measures: which interpretation?

Affiliations

¹ INSERM U 1035, University of Bordeaux, France.
² Department of Dermatology, Kyoto Prefectural University of Medicine, Kyoto, 602-8566, Japan.

Comment

A Taïeb et al. Br J Dermatol. 2021 Sep.

. 2021 Sep;185(3):479-480.

doi: 10.1111/bjd.20424. Epub 2021 May 31.

¹ INSERM U 1035, University of Bordeaux, France.
² Department of Dermatology, Kyoto Prefectural University of Medicine, Kyoto, 602-8566, Japan.

No abstract available

Comment on

Dupilumab treatment in patients with atopic dermatitis: a comparative cohort study between the Netherlands and Japan shows a discrepancy in patient-reported outcome measures.
de Wijs LEM, Fujimoto RFT, Andrinopoulou ER, Nijsten T, Hijnen D, Kataoka Y. de Wijs LEM, et al. Br J Dermatol. 2021 Sep;185(3):555-562. doi: 10.1111/bjd.19897. Epub 2021 Jun 8. Br J Dermatol. 2021. PMID: 33657668 Free PMC article.

1. de Wijs LEM, Fujimoto RFT, Andrinopoulou ER et al. Dupilumab treatment in patients with atopic dermatitis: a comparative cohort study between the Netherlands and Japan shows a discrepancy in patient-reported outcome measures. Br J Dermatol 2021; 185:555-62.
1. Silverberg JI, Margolis DJ, Boguniewicz M et al. Validation of five patient-reported outcomes for atopic dermatitis severity in adults. Br J Dermatol 2020; 182:104-11.
1. Kunz B, Oranje AP, Labrèze L et al. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology 1997; 195:10-19.
1. Stalder JF, Barbarot S, Wollenberg A et al. Patient-Oriented SCORAD (PO-SCORAD): a new self-assessment scale in atopic dermatitis validated in Europe. Allergy 2011; 66:1114-21.